歐康維視生物-B(01477.HK)公佈年度業績，營收大增328.73%，產品管線已擴充至20個藥物資產
格隆匯3月25日丨歐康維視生物-B(01477.HK)發佈公吿，截至2021年12月31日止年度，公司收益為人民幣5614.6萬元，同比增長328.73%；年內虧損為人民幣2.60億元，去年同期則虧損為22.65億元，基本每股虧損為人民幣0.43分。
公吿稱，收益增加乃主要歸因於(i)眼科產品(即歐沁®、酒石酸溴莫尼定滴眼液、OT-401及康姝)的銷售額大幅增加，主要是由於公司在醫院營銷及推廣該等產品的工作進展順利；及(ii)有關埃美丁®及貝特舒®的以銷售為基礎的特許權使用費收入增加。
截至2021年12月31日止年度，公司的經調整研發支出(未經國際財務報吿準則調整)為人民幣4.547億元，同比增長27.9%。該增加主要由於公司的管線產品數量以及公司處於臨牀試驗及非臨牀試驗階段候選藥物的研發活動增加，部分研發開支因於報吿期內相應候選藥物進入III期臨牀試驗階段而被資本化。
於報吿期內，公司產品管線已擴充至20個藥物資產，其中六種候選藥物已進入III期臨牀試驗階段，涵蓋所有主要的眼睛前部及後部疾病。公司的候選藥物覆蓋葡萄膜炎、小兒近視、結膜炎、青光眼、濕性老年黃斑病變及糖尿病黃斑水腫等諸多眼科用藥急需領域。公司在III期臨牀試驗的重大進展使公司在中國眼科創新藥領域佔據領先地位，是目前在CDE登記進行III期臨牀試驗的創新眼科藥物數量最多的企業。
於報吿期內，公司臨牀研發項目斬獲多項重要里程碑。OT-401(氟輕鬆玻璃體內植入劑)、OT-1001(鹽酸西替利嗪滴眼液)、OT-702(阿柏西普生物類似藥)、OT-301(一氧化氮與前列腺素合成的新化合物)、OT-101(硫酸阿托品滴眼液)及OT-502(地塞米松植入劑)6款候選藥物處於III期臨牀試驗，內部開發治療乾眼症1類新藥OT-202(酪氨酸激酶抑制劑)進入臨牀試驗階段。
於報吿期內，公司積極推進公司的商業化產品並實現總醫院終端銷售收入(未經審核)約人民幣90百萬元，較截至2020年12月31日止年度增長466.53%。公司繼續加快公司藥物滲透至中國眼科市場的醫院，實現覆蓋全國1,024家醫院，其中59家為三級醫院。
截至公吿日期，公司在蘇州生產場所的工程已完成並已開始試生產。該佔地約30,000平方米的現代化眼科生產基地僅耗用496天即已建成。該生產場所共有四個生產車間，設計年產能最高預計將達455百萬劑藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
